Equities analysts forecast that Haemonetics Co. (NYSE:HAE) will announce $0.59 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Haemonetics’ earnings, with estimates ranging from $0.57 to $0.62. Haemonetics posted earnings of $0.62 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 4.8%. The business is scheduled to announce its next earnings results on Tuesday, February 5th.
On average, analysts expect that Haemonetics will report full year earnings of $2.33 per share for the current year, with EPS estimates ranging from $2.30 to $2.37. For the next fiscal year, analysts anticipate that the company will report earnings of $3.04 per share, with EPS estimates ranging from $2.61 to $3.40. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Haemonetics.
Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. The business had revenue of $241.58 million during the quarter, compared to analysts’ expectations of $233.44 million. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the company posted $0.48 earnings per share.
A number of research firms have commented on HAE. Barrington Research raised their price target on shares of Haemonetics from $90.00 to $118.00 and gave the stock an “outperform” rating in a report on Thursday, August 9th. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price target for the company in a report on Friday, October 12th. Morgan Stanley raised their price target on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, August 8th. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 7th. Finally, TheStreet cut shares of Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $113.20.
NYSE:HAE traded down $3.47 during trading hours on Friday, reaching $111.61. The company had a trading volume of 667,800 shares, compared to its average volume of 461,515. The company has a current ratio of 2.92, a quick ratio of 1.94 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $5.95 billion, a price-to-earnings ratio of 59.68, a PEG ratio of 3.67 and a beta of 1.09. Haemonetics has a twelve month low of $53.74 and a twelve month high of $117.56.
In other news, Director Pedro P. Granadillo sold 30,824 shares of Haemonetics stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $111.83, for a total transaction of $3,447,047.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO William P. Mr. Burke sold 841 shares of Haemonetics stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $46.76, for a total transaction of $39,325.16. The disclosure for this sale can be found here. Insiders have sold 62,653 shares of company stock valued at $6,973,391 over the last quarter. Corporate insiders own 1.04% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. DekaBank Deutsche Girozentrale grew its holdings in shares of Haemonetics by 18.7% during the third quarter. DekaBank Deutsche Girozentrale now owns 13,749 shares of the medical instruments supplier’s stock valued at $1,513,000 after buying an additional 2,165 shares during the last quarter. CIBC World Markets Inc. acquired a new position in shares of Haemonetics during the third quarter valued at about $233,000. Globeflex Capital L P acquired a new position in shares of Haemonetics during the third quarter valued at about $268,000. Jackson Square Partners LLC grew its holdings in shares of Haemonetics by 15.6% during the third quarter. Jackson Square Partners LLC now owns 1,439,167 shares of the medical instruments supplier’s stock valued at $164,899,000 after buying an additional 194,045 shares during the last quarter. Finally, Cim Investment Mangement Inc. acquired a new position in shares of Haemonetics during the third quarter valued at about $545,000. Hedge funds and other institutional investors own 96.44% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Further Reading: Fundamental Analysis and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.